New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
09:21 EDTAZN, TEVA, MNTA, CBEY, ATHN, ACTG, AMD, ABX, NEM, NUS, RNA, SRPT, PFE, MUOn The Fly: Pre-Market Movers
HIGHER: Sarepta (SRPT), up 54% after announcing plans to to submit NDA for Eteplirsen by year end 2014. Shares of Prosnesa (RNA), another drugmaker working on a competing DMD drug, are up more than 12%... AstraZeneca (AZN), up 6% after the Sunday Times says that Pfizer (PFE) is considering a takeover bid for the company. Pfizer is up 1.2% following the report... Newmont Mining (NEM), up 8% after WSJ says the company and Barrick Gold (ABX) could resume merger talks as soon as today... Cbeyond (CBEY), up 39% after agreeing to be acquired for about $323M by Birch Communications... Momenta Pharma (MNTA), up 10.5% after the Supreme Court rejected Teva's (TEVA) bid to delay generic Copaxone... Nu Skin (NUS), up 5% after saying its China division will resume corporate-hosted business meetings... Micron (MU), up 4% after price target raised at Drexel Hamilton... DOWN AFTER EARNINGS: Acacia Research (ACTG), down 6%... athenahealth (ATHN), down 5.6%.
News For AZN;PFE;SRPT;RNA;NUS;NEM;ABX;AMD;ACTG;ATHN;CBEY;MNTA;TEVA;MU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
October 20, 2014
11:13 EDTNUSNu Skin volatility elevated
Nu Skin October weekly call option implied volatility is at 95, November is at 73, December is at 72; compared to its 26-week average of 48 according to Track Data, suggesting decreasing price movement.
09:09 EDTSRPTEMA encourages applications for orphan designation for Ebola treatments
The European Medicines Agency encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation, the regulator announced. Drug companies that are working on experimental Ebola vaccines and treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX), NewLink Genetics (NLNK) and GlaxoSmithKline (GSK).
08:30 EDTNUSNu Skin initiated with a Buy at Pivotal Research
Target $75.
07:47 EDTAZN, PFEPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:19 EDTAZNIBC Life Sciences to hold a conference
Subscribe for More Information
07:15 EDTPFEAmerican Academy of Child & Adolescent Psychiatry to hold annual meeting
Subscribe for More Information
07:14 EDTAZNEuropean College of Neuropsychopharmacology to hold a conference
27th ECNP Congress is being held in Berlin, Germany on October 18-21.
07:12 EDTPFECongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:11 EDTPFEAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTPFEAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
06:53 EDTMUMicron upgraded to Outperform from Sector Perform at Pacific Crest
Subscribe for More Information
06:50 EDTRNAProsensa upgraded to Overweight from Underweight at JPMorgan
JPMorgan upgraded Prosensa two notches to Overweight citing a favorable risk/reward around the potential approval of Drisapersen for Duchenne muscular dystrophy. The firm believes regulatory risk for the drug has been significantly reduced in both the U.S. and Europe. JPMorgan raised its price target for shares to $18 from $4.40.
06:38 EDTATHNathenahealth price target lowered to $115 from $140 at RBC Capital
Subscribe for More Information
06:28 EDTTEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
06:17 EDTNEMNewmont Mining upgraded to Buy from Neutral at Citigroup
Subscribe for More Information
06:04 EDTACTGAcacia Research subsidiary enters into agreement with BlackBerry
Acacia Research announced that its Cell and Network Selection subsidiary entered into an agreement with Blackberry Corporation and Blackberry Limited (BBRY). The agreement resolved litigation that was pending between Cell and Network Selection and Blackberry in the U.S. District Court for the Eastern District of Texas.
06:02 EDTACTGAcacia Research subsidiary enters into patent license agreement with Vanguard
Subscribe for More Information
05:58 EDTMUMicron upgraded to Outperform from Sector Perform at Pacific Crest
October 19, 2014
16:44 EDTSRPTEbola drug discovery efforts intensify, WSJ says
Subscribe for More Information
13:39 EDTSRPTCarnival cruise passenger tests negative for Ebola, Reuters says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use